Medication info
Esomeprazole Magnesium Hydrate 40 mg

Esomeprazole Magnesium Hydrate 40 mg

Prescription medicationTabletOral · Intravenous injection
Ingredient · strength
Esomeprazole Magnesium Dihydrate›43.38mg / 1 tablet
Manufacturer / importer
COSMAX Pharma Co., Ltd.
Appearance
Pink round film-coated tablets
Packaging
28 tablets (14 tablets/AluAlu x 2)
Approval status
Active

MFDS item code 201900295 · Approved 2019.01.22 · Insurance code 055100620

Summary

Main use
Reflux and Zollinger-Ellison syndrome, gastrointestinal disorders caused by anti-inflammatory analgesics, and eradication, treatment, and prevention of ulcers
Who uses it
Adults · Children
Adult dosage
This medication should be swallowed with a liquid such as water and should not be chewed or crushed. 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis has not healed or symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, control any subsequent symptoms by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. For patients at high risk of developing gastric or duodenal ulcers due to nonsteroidal anti-inflammatory drug therapy, as-needed administration is not recommended for control of recurring symptoms. 2) Combination therapy with antibiotics for the eradication of Helicobacter pylori Administer 20 mg of this medication in combination with 1 g of amoxicillin and 500 mg of clarithromycin twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical trials extending beyond 4 weeks have not been conducted. 4) Patients requiring ongoing treatment with nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug therapy: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug therapy: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should then be adjusted for each patient, and treatment should be continued for as long as clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses exceeding 80 mg per day should be divided and administered twice daily. 6) Maintenance therapy following intravenous induction of prevention of rebleeding from gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous induction of prevention of rebleeding from gastric or duodenal ulcers. No dose adjustment is necessary. Use with caution in patients with severe renal impairment, as there is limited experience in these patients. No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, do not exceed a dose of 20 mg of this medication. No dose adjustment is necessary.
Children's dosage
Adolescents aged 12 years and over - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis has not healed or symptoms persist, continue treatment for an additional 4 weeks. Adolescents aged 12 years and over - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Adolescents aged 12 years and over - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, control any subsequent symptoms by administering 20 mg once daily. Children under 12 years of age: There is no experience with administration of this medication to children under 12 years of age.

Ingredients

Manufacturer
COSMAX Pharma Co., Ltd.

Efficacy & effects

Reflux and Zollinger-Ellison syndrome, gastrointestinal disorders caused by anti-inflammatory analgesics, and eradication, treatment, and prevention of ulcers

  • Gastroesophageal reflux disease
  • erosive esophagitis
  • esophagitis
  • duodenal ulcers
  • peptic ulcers
  • upper gastrointestinal symptoms
  • pain
  • discomfort
  • burning sensation
  • gastric ulcers
  • duodenal ulcers
  • Zollinger-Ellison syndrome
View approved original text

This medication is used for the treatment of gastroesophageal reflux disease and improvement of erosive esophagitis. It also helps with long-term maintenance therapy to prevent recurrence in patients with esophagitis and alleviate symptoms of gastroesophageal reflux disease without esophagitis. It is effective in treating and preventing recurrence of duodenal ulcers and peptic ulcers caused by Helicobacter pylori infection. Additionally, it is utilized for symptoms in the upper gastrointestinal tract associated with non-steroidal anti-inflammatory drugs, and for the treatment of gastric ulcers and prevention of related ulcers. It is used in the treatment of Zollinger-Ellison syndrome and is suitable for maintenance therapy after preventing rebleeding from gastric or duodenal ulcers. This medication is broadly used for treatment and prevention of various gastrointestinal diseases.

Dosage and Administration

Adult dosage

This medication should be swallowed with a liquid such as water and should not be chewed or crushed. 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis has not healed or symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, control any subsequent symptoms by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. For patients at high risk of developing gastric or duodenal ulcers due to nonsteroidal anti-inflammatory drug therapy, as-needed administration is not recommended for control of recurring symptoms. 2) Combination therapy with antibiotics for the eradication of Helicobacter pylori Administer 20 mg of this medication in combination with 1 g of amoxicillin and 500 mg of clarithromycin twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical trials extending beyond 4 weeks have not been conducted. 4) Patients requiring ongoing treatment with nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug therapy: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug therapy: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should then be adjusted for each patient, and treatment should be continued for as long as clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses exceeding 80 mg per day should be divided and administered twice daily. 6) Maintenance therapy following intravenous induction of prevention of rebleeding from gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous induction of prevention of rebleeding from gastric or duodenal ulcers. No dose adjustment is necessary. Use with caution in patients with severe renal impairment, as there is limited experience in these patients. No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, do not exceed a dose of 20 mg of this medication. No dose adjustment is necessary.

Children's dosage

Adolescents aged 12 years and over - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis has not healed or symptoms persist, continue treatment for an additional 4 weeks. Adolescents aged 12 years and over - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Adolescents aged 12 years and over - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, control any subsequent symptoms by administering 20 mg once daily. Children under 12 years of age: There is no experience with administration of this medication to children under 12 years of age.

Precautions

This medication should not be used in certain patients. For example, patients who are allergic or have had adverse reactions to this medication or its ingredients, or to benzimidazole derivatives, should not take it. Additionally, patients with hypersensitivity to penicillin antibiotics or macrolide antibiotics should not take this medication when combined with those antibiotics for the eradication of Helicobacter pylori. Patients or nursing mothers taking certain medications, such as terfenadine, cisapride, pimodidine, astemizole, atazanavir, nelfinavir, or rilpivirine, should avoid using this medication. This medication can cause various side effects, which may include blood-related problems such as leukopenia, thrombocytopenia, and agranulocytosis, which are rare. Immunologically, symptoms like fever, angioedema, and severe allergic reactions may occur. In metabolic and nutritional aspects, edema, hyponatremia, and hypomagnesemia have been reported; hypomagnesemia could also affect calcium and potassium levels. Mental health issues such as insomnia, anxiety, confusion, depression, and rarely aggression or hallucinations may arise. Common neurological side effects include headaches, dizziness, and drowsiness. Gastrointestinal issues may include abdominal pain, constipation, diarrhea, nausea, and vomiting, with rare reports of pancreatitis or gastroenteritis. Liver function abnormalities or jaundice can occur, and liver failure may rarely happen, necessitating caution regarding liver health. Dermatological reactions may include rashes, itching, hair loss, and severe skin reactions such as Stevens-Johnson syndrome in severe cases. Musculoskeletal issues like fractures, arthralgia, myalgia have also been reported. Long-term use of this medication requires regular checks for abnormalities. It can suppress gastric acid secretion, possibly promoting bacterial growth in the stomach and slightly increasing infection risk. This is particularly important in hospitalized patients, who may have a higher risk of diarrhea caused by Clostridium difficile. Furthermore, this medication may increase the risk of osteoporotic fractures, so patients at risk of fractures require proper monitoring. This medication can interact with certain drugs, so it is essential to consult with a doctor or pharmacist if other medications are being taken. The safety of this medication during pregnancy has not been fully established, so caution is advised; it is also best not to take it during breastfeeding. In case of overdose, there are no specific antidotes; appropriate treatment should be provided based on symptoms. It should be stored out of reach of children.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, confusion, depression, aggression, hallucinations, headache, dizziness, paresthesia, drowsiness, taste disturbance, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal bloating, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, alopecia, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, Lyell's syndrome, acute generalized exanthematous pustulosis, eosinophilia, drug reaction with systemic symptoms, fracture, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile associated diarrhea, abdominal distention, allergic reaction, back pain, chest pain, sternal pain, facial edema, facial flushing, fatigue, fever, influenza-like illness, generalized edema, leg edema, malaise, pain, stiffness, peripheral edema, flushing, hypertension, tachycardia, thyroid nodule, irritable bowel syndrome, exacerbation of constipation, dyspepsia, dysphagia, gastrointestinal malformation, epigastric pain, belching, esophageal disorder, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, melena, oral disorders, pharyngeal disorders, rectal disorders, gastrointestinal symptoms, increased serum gastrin, tongue disorders, tongue swelling, ulcerative stomatitis, earache, tinnitus, anemia, hypochromic anemia, cervical lymphadenopathy, nosebleeds, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, abnormal liver function, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, polydipsia, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, seizures, fibromyalgia syndrome, hernia, rheumatoid polymyalgia, loss of appetite, apathy, increased appetite, confusion, worsening depression, hypertonia, sensory decrease, erectile dysfunction, insomnia, migraine, exacerbation of migraine, sleep disorders, tremors, visual field defects, dysmenorrhea, menstrual disorders, vaginitis, worsening asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, erythematous rash, papular rash, otitis media, abnormal olfaction, taste loss, taste distortion, urinary abnormalities, albuminuria, cystitis, dysuria, fungal infection, hematuria, urinary frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyp, mucosal discoloration, hernia, hypocalcemia, hypokalemia, rhabdomyolysis, myalgia, elevated creatine kinase, increased serum and urinary myoglobin, cutaneous lupus erythematosus, systemic lupus erythematosus

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to protect it from air and moisture; the ideal storage temperature is room temperature between 1°C and 30°C. Storing it this way helps maintain the efficacy of the medication for a longer period.

Appearance and packaging

Appearance

Pink round film-coated tablets

Package unit

28 tablets (14 tablets/AluAlu x 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.